Oncolines B.V.

𝗪𝗼𝗿𝗹𝗱 𝗛𝗲𝗮𝗹𝘁𝗵 𝗗𝗮𝘆 𝟮𝟬𝟮𝟱 Once limited to chemotherapy and radiation, cancer treatment is now rapidly evolving, powered by remarkable scientific breakthroughs. This World Health Day, we’re highlighting key oncology trends that are reshaping cancer care in 2025: ✔️ 𝗗𝗿𝘂𝗴𝗴𝗶𝗻𝗴 𝘁𝗵𝗲 "𝘂𝗻𝗱𝗿𝘂𝗴𝗴𝗮𝗯𝗹𝗲" Recent breakthroughs have enabled the development of therapies against previously elusive targets. 𝐾𝑅𝐴𝑆 G12C mutations, once deemed "undruggable," can now be targeted with FDA-approved inhibitors such as sotorasib and adagrasib—offering new treatment options for patients with select tumor types. ✔️ 𝗕𝗲𝗮𝘁𝗶𝗻𝗴 𝗰𝗮𝗻𝗰𝗲𝗿 𝗱𝗿𝘂𝗴 𝗿𝗲𝘀𝗶𝘀𝘁𝗮𝗻𝗰𝗲 Innovative strategies are being explored to combat drug resistance. For example, stabilizing tumor suppressor proteins like p53 has shown promise in restoring apoptosis in cancer cells, offering a potential path to overcome therapeutic resistance. ✔️ 𝗘𝗺𝗲𝗿𝗴𝗶𝗻𝗴 𝘁𝗮𝗿𝗴𝗲𝘁𝗲𝗱 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 Cyclic peptides are gaining attention for their ability to selectively bind to cancer cell receptors and disrupt tumor growth pathways. These molecules are progressing through preclinical development as a promising class of targeted therapies. ✔️ 𝗖𝗼𝗺𝗯𝗶𝗻𝗮𝘁𝗶𝗼𝗻 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 𝗳𝗼𝗿 𝗴𝗿𝗲𝗮𝘁𝗲𝗿 𝗶𝗺𝗽𝗮𝗰𝘁 As more cancer treatments rely on drug combinations, there’s a growing focus on identifying synergistic pairs and using companion diagnostics to match patients to the most effective, personalized, and economically viable regimens. ✔️  𝗔𝗜-𝗱𝗿𝗶𝘃𝗲𝗻 𝗱𝗿𝘂𝗴 𝗱𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 Artificial intelligence is accelerating oncology drug discovery by predicting drug–target interactions, optimizing compound design, and identifying biomarkers—helping streamline the path to more effective treatments. At Oncolines, we support these innovations through advanced Cancer Cell Line Profiling, Drug Sensitivity Screening, Biomarker Discovery, and SynergyScreen™ combination analysis—accelerating the development of targeted therapies and driving precision oncology forward. Visit our website to learn more! #WorldHealthDay2025 #PrecisionOncology #CancerResearch

𝗢𝗻𝗰𝗼𝗹𝗶𝗻𝗲𝘀 𝗖𝗮𝘀𝗲 𝗦𝘁𝘂𝗱𝘆 – Measuring Drug Synergy in Oncology Research How do you know if a drug combination is truly synergistic, and not just additive? At Oncolines, we apply advanced methodologies to identify and quantify these interactions, helping researchers in making informed decisions during cancer drug development. Our key approaches include: • 𝗦𝘆𝗻𝗲𝗿𝗴𝘆𝗙𝗶𝗻𝗱𝗲𝗿™ - Evaluate your lead compound in combination with standards of care or novel agents using fixed-ratio assays based on IC₅₀ values. Quickly identify synergistic pairs to move forward with confidence. • 𝗖𝗼𝗺𝗯𝗶𝗻𝗮𝘁𝗶𝗼𝗻 𝗠𝗮𝘁𝗿𝗶𝘅 𝗔𝗻𝗮𝗹𝘆𝘀𝗶𝘀 - Visualize synergy across dose ranges using full dose-response curves for both compounds. Synergy is quantified with the Bliss Independence Score, revealing where your combination has the greatest effect. • 𝗦𝘆𝗻𝗲𝗿𝗴𝘆𝗦𝗰𝗿𝗲𝗲𝗻™ 𝗣𝗹𝗮𝘁𝗳𝗼𝗿𝗺 - Discover promising drug classes for combination therapy. Your compound is screened against a panel of 42 anti-cancer agents, each representing a distinct molecular mechanism, helping uncover high-potential synergies efficiently. Our case studies offer real-world examples of how our scientific capabilities translate into actionable insights — helping you de-risk R&D, optimize drug combinations, and accelerate progress. 👉 Explore more case studies on our website [link in comments]. #CaseStudy #DrugSynergy #CancerResearch

Thank you Sabrina Corazza, Iolanda Micco, Loredana Redaelli, Atf NAGBOU and Gianluca Conti for the warm welcome and nice discussions.

Welcome Hanjo Kim at Symeres! Today, Hanjo Kim, representing Oncolines B.V., Symeres and Admescope in Korea visited our site. Looking forward to our collaboration and further growing our business in South-Korea.

Enjoying the early spring sun during lunch in downtown Oss 😎

📢𝗥𝗘𝗔𝗗𝗰𝗼𝗺𝗺𝗲𝗻𝗱𝗮𝘁𝗶𝗼𝗻: 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗿𝗲𝗹𝗲𝘃𝗮𝗻𝗰𝗲 𝗼𝗳 𝗸𝗶𝗻𝗮𝘀𝗲 𝘀𝗲𝗹𝗲𝗰𝘁𝗶𝘃𝗶𝘁𝘆 𝗶𝗻 𝗩𝗘𝗚𝗙𝗥𝟮-𝘁𝗮𝗿𝗴𝗲𝘁𝗶𝗻𝗴 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 A study published by Seong Jang et al. in 𝘊𝘢𝘯𝘤𝘦𝘳 𝘊𝘩𝘦𝘮𝘰𝘵𝘩𝘦𝘳𝘢𝘱𝘺 𝘢𝘯𝘥 𝘗𝘩𝘢𝘳𝘮𝘢𝘤𝘰𝘭𝘰𝘨𝘺 demonstrates how biochemical kinase profiling can help evaluate the selectivity of VEGFR2 inhibitors. The research compares rivoceranib to 10 FDA-approved VEGFR2 inhibitors across a panel of 270 kinases, revealing key differences in potency and off-target effects. 𝗞𝗲𝘆 𝗳𝗶𝗻𝗱𝗶𝗻𝗴𝘀: ✔ Rivoceranib is identified as a highly selective VEGFR2 inhibitor. ✔ Differences in selectivity among VEGFR2 inhibitors are clinically relevant, as off-target effects contribute to toxicity. ✔ Biochemical kinase profiling provides quantitative insights into inhibitor selectivity, supporting rational therapy selection and potentially reducing off-target toxicities. At Oncolines, we provide broad kinase activity profiling to evaluate your compound selectivity and potency across a diverse kinase panel. Our Kinome Profiling service helps researchers and drug developers make informed decisions to optimize selectivity, reduce toxicities, and enhance therapeutic potential. Read the full study: [Link in the comments] #READcommendation #VEGFR2 #KinaseInhibitor #ComparativeKinaseActivity

𝗜𝗻𝘁𝗿𝗼𝗱𝘂𝗰𝗶𝗻𝗴 𝘁𝗵𝗲 𝗻𝗲𝘅𝘁 𝗳𝗲𝗮𝘁𝘂𝗿𝗲 𝗶𝗻 𝗼𝘂𝗿 𝗦𝗲𝗿𝘃𝗶𝗰𝗲 𝗦𝗽𝗼𝘁𝗹𝗶𝗴𝗵𝘁 𝗦𝗲𝗿𝗶𝗲𝘀! This month, we’re excited to present 𝗢𝗻𝗰𝗼𝗹𝗶𝗻𝗲𝘀 𝗕𝗶𝗼𝗰𝗵𝗲𝗺𝗶𝘀𝘁𝗿𝘆 𝗦𝗲𝗿𝘃𝗶𝗰𝗲𝘀, designed to support your drug discovery with reliable, high-quality enzymatic and binding assays. Selecting the best drug candidate for your target requires a deep understanding of compound binding characteristics. Several biochemical techniques can be applied to identify the compound with the most promising properties for further analysis.  Our protein and biophysical scientists collaborate closely with you to design the most suitable assay format for your study and provide valuable scientific insights. Explore the carousel to discover how Oncolines Biochemistry Services can accelerate your research! Learn more via the link in the comments. #Biochemistry #DrugDiscovery #BindingAssays #EnzymaticAssays

Meet us at our poster (#73P) or Booth (#4) at the ESMO Targeted Anticancer Therapies (TAT) conference in Paris, 3-5 March.

Meet Us in Paris at ESMO - European Society for Medical Oncology Targeted Anticancer Therapies Congress 2025! 📍 Visit us at Booth #4 📅 March 3-5, 2025 | Paris, France 📊 Poster Presentation (#73P): March 3rd Join us for our poster presentation on kinase-targeting agents and cell signaling modulators, titled “Combined cellular and biochemical profiling of BTK inhibitor nemtabrutinib reveals potential application in MAPK pathway-driven cancers.” Our experts, Guido Zaman and Dimitri Pappaioannou will be available to discuss how the Oncolines® cancer cell panel profiling, bioinformatics analyses and biochemical kinase profiling can reveal previously underappreciated cross-reactivities and provide potential novel therapeutic applications of nemtabrutinib. Connect with us at Booth #4 and explore how Oncolines can support your drug discovery efforts! #ESMO #TargetedTherapies #CancerDrugDiscovery

𝗔𝗜 𝗮𝗻𝗱 𝗠𝗮𝗰𝗵𝗶𝗻𝗲 𝗟𝗲𝗮𝗿𝗻𝗶𝗻𝗴 are reshaping precision oncology, enabling faster biomarker analysis, automated diagnostics, and deeper insights into the tumor microenvironment. These advancements provide new ways to analyze vast datasets, paving the way for: ✔ Earlier detection ✔ Optimized treatment selection ✔ Improved patient outcomes However, full integration into cancer care requires further validation through large, prospective clinical studies. Overcoming challenges such as data privacy, clinical validation, and seamless integration into medical workflows will be essential to unlocking AI’s full potential. Swipe through to explore key highlights of AI’s impact on oncology! Read the full study: Fountzilas et al., 2025. Convergence of Evolving Artificial Intelligence and Machine Learning Techniques in Precision Oncology. npj Digital Medicine. 📢 Share this post to spread awareness about AI’s role in cancer care!  #PrecisionOncology #AI #MachineLearning #DigitalPathology